Browse Biomarkers Based on Source

This page shows data for Blood source.
Total Entries Retrieved: 245
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
404 Total cholesterol Metabolites Humans Downregulated with Low Fat Diet [ Control Diet: 196 (95% CI: 180-226), Low Fat Diet: 182 (95% CI: 161-192)] Predictive Controls Vs Low Fat Supplementation in patients with PCa p = 0.048 Blood 19064574
405 Low-density cholesterol Metabolites Humans Downregulated with Low Fat Diet [ Control Diet: 111 (95% CI: 90-128), Low Fat Diet: 105 (95% CI: 90-124)] Predictive Controls Vs Low Fat Supplementation in patients with PCa p=0.032 Blood 19064574
447 CTC (Circulating Tumor Cells) Others Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
448 Alkaline Phosphatase Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
449 LDH Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
450 Prostatic Acid Phosphatase (PAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
451 Total Acid Phosphatase (TAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
452 Albumin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p=0.002 Blood 19505924
453 Hemoglobin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
456 MIC-1 (Macrophage inhibitory cytokine 1) Protein Humans Downregulated after one round of chemotherapy Predictive Metastatic HRPC patients Pre Vs Post One round of Docetaxel chemotherapy p=0.02 Blood 19773444
457 MIC-1 (Macrophage inhibitory cytokine 1) Protein Humans Downregulated after one round of chemotherapy Predictive Overall survival Vs No survival in patients Post One round of Docetaxel chemotherapy p=0.002 Blood 19773444
509 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in Metastatis (Metastatis: 1.81±0.153; Healthy: 1.0 ± 0.132) Diagnostic Healthy Vs Metastatic p<0.001 Blood 20043080
533 PSA (G/G Genotype) Mutation Humans Increases risk with G/G Genotype compared with the G/A And A/A genotype Diagnostic Cancer Vs Controls p<0.05 Blood 20632874
534 AR: (Short CAG) Mutation Humans Increased Risk with shorter CAG Repeats Diagnostic Cancer Vs Controls p = 0.007 Blood 20632874
535 PSA and AR (G/G and Short CAG) Mutation Humans Increased Risk of Prostate Cancer Diagnostic Cancer Vs Controls p = 0.0418 Blood 20632874
536 PSA (G/G Genotype) Mutation Humans Increases risk of Gleason Score >=7 with G/G Genotype compared with the G/A & A/A genotype Prognostic Gleason ≤7 Vs Gleason Score >7 p= 0.0122 Blood 20632874
537 AR: (Short CAG) Mutation Humans Increased RIsk of GS (4+3) with Short CAG Repeats Prognostic Gleason Score 7 (4+3) Vs Gleason Score 7 (3+4) p = 0.045 Blood 20632874
569 D-Dimer Protein Humans Upregulated in Progressive Disease Prognostic progressive disease (PD) Vs nonprogressive disease (non-PD) p<0.024 Blood 21088161
585 SLCO2B1 (SNP rs12422149) Mutation Humans Increased risk in GA or AA type allele Prognostic Prostate Cancer Specific Mortality No No mortality p<0.05 Blood 21266523
586 SLCO1B3 (SNP rs4149117) Mutation Humans NA Prognostic Prostate Cancer Specific Mortality No No mortality p<0.05 Blood 21266523
615 Mutation Status of TNFSF10 (SNP: rs3774315 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: 0.0000734; Testing Set: p=0.03 Blood 21467234
616 Mutation Status of FBXO34 (SNP: rs8015211 (T/C)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000164 Blood 21467234
617 Mutation Status of FBXO34 (SNP: rs12433615 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000406 Blood 21467234
618 Mutation Status of FBXO34 (SNP: rs1188069 (T/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000638 Blood 21467234
619 Mutation Status of FBXO34 (SNP: rs2341883 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000638 ; Testing Set: 0.01 Blood 21467234
620 Mutation Status of HERC2 (SNP: rs6497287 (T/C)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.000052 ; Test Set: p=0.004 Blood 21467234
621 Mutation Status of WWOX (SNP: rs11150069 (C/A)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.00000943 Blood 21467234
622 Mutation Status of WWOX (SNP: rs4628973 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.000000462 Blood 21467234
623 Mutation Status of IL1RAPL1 (SNP: rs225061 (G/T)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.000971 Blood 21467234
624 Mutation Status of TNFSF10 (SNP: rs3774315 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic Less Aggressive Vs Controls Discovery Set: 0.0000734; Testing Set: p=0.002 Blood 21467234
625 Mutation Status of FBXO34 (SNP: rs2341883 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic Less Aggressive Vs Controls Discovery Set: p= 0.0000638 ; Testing Set: 0.01 Blood 21467234
674 Circulating Tumor Cells (Base Line) Others Humans NA Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p<0.001 Blood 21705286
675 Circulating Tumor Cells (Post Base Line) Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p<0.001 Blood 21705286
676 Alkaline Phosphate Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p=0.006 Blood 21705286
677 Lactate Dehydrogenase (LDH) Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p<0.001 Blood 21705286
678 Testosterone Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p=0.005 Blood 21705286
705 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls NA Blood 21832279
724 Mutation Status of PER1, SNP: rs885747 Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
725 Mutation Status of PER1, SNP rs2289591 - T/T Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
726 Mutation Status of PER1, SNP: rs885747 - G/T + T/T Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
727 Mutation Status of PER2, SNP: rs7602358: T/G phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
728 Mutation Status of PER2, SNP: rs7602358: T/G+G/G phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
729 Mutation Status of PER3,SNP: rs1012477: C/G phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
730 Mutation Status of PER3,SNP: rs1012477: C/G + C/C phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
731 Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
732 Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
733 Mutation Status of CRY1 SNP: rs12315175 ; C/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
734 Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
735 Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
736 Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
737 Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
738 Mutation Status of CLOCK, SNP: rs11133373, G/G Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
739 Mutation Status of CLOCK, SNP: rs11133373, G/G + C/G Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
740 Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
741 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
742 Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
743 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
744 Mutation Status of NPAS2, SNP: rs895521 G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
745 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
746 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
747 Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
748 Mutation Status of NPAS2, SNP: rs1369481, T/C + CC Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
749 Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
750 Mutation Status of NPAS2, SNP: rs1369481, C/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
751 Mutation Status of NPAS2, SNP: rs1369481, T/C+C/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
773 Catalase Protein Humans Downregulated in PCA Diagnostic Controls Vs Patients p<0.05 Blood 21993000
774 Superoxide Dismutase Protein Humans Upregulated in PCA Diagnostic Controls Vs Patients p<0.05 Blood 21993000
800 PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2; mRNA Humans Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
801 LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1; mRNA Humans Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination p< 0.008 Blood 22071976
802 RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; SNCA; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; ALAS2; CAMP; LCN2; OLFM4; DEFA3; DEFA1; DEFA1; DEFA1; ERAF; CA1; HBD; DEFA1; mRNA Humans Upregulated Postvaccine treatment: [RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; CAMP; LCN2; OLFM4; DEFA3; DEFA1;ERAF; CA1; HBD;] Predictive Short Term Survival Pre Vs Post Vaccination p< 0.008 Blood 22071976
803 LRRN3+PCDH17+HIST1H4C+PGLYRP1 mRNA Humans Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
807 %p2PSA Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
808 Prostate Helth Index (phi) Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
809 %p2PSA Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
810 Prostate Helth Index (phi) Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
811 %p2PSA Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
812 Prostate Helth Index (phi) Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
896 Ring finger protein 19A (RNF19A) mRNA Humans Upregulated in PCa (>2 fold) Diagnostic Prostate Cancer vs healthy controls p = 0.0066 Blood 22493721
941 Mutation Status of KLK3 (-5429 T/G (rs2569733)) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.013 Blood 22759231
942 Mutation Status of KLK2 (Arg250Trp (rs198977)) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: p=0.025 ; Multivariate Analysis : p=0.044 Blood 22759231
943 Mutation Status of SULT1A1, Arg213His (rs9282861) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: 0.014 Blood 22759231
944 Mutation Status of BGLAP, -198 T/C (rs1800247) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.020 Blood 22759231
945 Mutation Status of KLK3 + KLK2 + SULT1A1 + BGLAP + Nonogram Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) p<0.001 Blood 22759231
996 GPX1 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
997 SOD2 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p=0.01 Blood 23046102
998 AR mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.001 Blood 23046102
999 Cyclin B mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.007 Blood 23046102
1000 bFGF mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.004 Blood 23046102
1001 2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF) mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
1002 ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A mRNA Humans NA Prognostic low-risk group Vs high-risk group p<0.05 Blood 23059047
1003 CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.58 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.0000346 Blood 23071848
1004 CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.59 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p=0.0000338 Blood 23071848
1005 FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.61 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.00000285 Blood 23071848
1006 KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.44 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000000182 Blood 23071848
1007 KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.66 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p=0.000000816 Blood 23071848
1008 TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1009 Combination of 6 genes duplexes [CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1010 PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3) + KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1011 PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3)+ KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1046 Hemoglobin Others Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Blood 23356551
1048 blood urea nitrogen (BUN) Others Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Blood 23356551
1051 Hemoglobin Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.001 Blood 23356551
1052 Hematuria Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.05 Blood 23356551
1053 RBC Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.05 Blood 23356551
1055 Circulating Tumor Cells (CTC) Others Humans Upregulated in mRCPC (CTC count >=3) Prognostic Locally Advanced Prostate Cancer (LaPC) Vs Metastatic Disease p < 0.001 Blood 23358719
1056 Circulating Tumor Cells (CTC) Others Humans Upregulated in patients with Lower Overall Survival (CTC count >=3) Prognostic Overall Survival p = 0.001 Blood 23358719
1143 RFX6 (rs339331) Mutation Humans Reduced Risk of Prostate cancer Diagnostic Cancer Vs Normal p= 0.013 Blood 23803082
1177 Genetic Risk score based on 41 SNPs (rs10187424, rs721048, rs1465618, rs13385191, rs12621278, rs2292884, rs4857841, rs6763931, rs10936632, rs17021918, rs12500426, rs7679673, rs2121875, rs12653946, rs130067, rs1983891, rs339331, rs9364554, rs10486567, rs6465657, rs1512268, rs1447295, rs6983561, rs16901979, rs10086908, rs12543663, rs620861, rs6983267, rs16902094, rs1016343, rs13252298, rs445114, rs10993994, rs4962416, rs10896449, rs11228565, rs12418451, rs10875943, rs9600079, rs4430796, rs11649743, rs1859962, rs8102476, rs17632542, rs2735839, rs9623117, rs5759167, rs5945619, rs5919432) Mutation Humans Increased Score with Increased risk of Prostate Cancer Diagnostic Prostate Cancer Vs no Prostate Cancer Univariate: p=0.014; Multivariate: 0.029 Blood 23891454
1178 SLCO2B1 rs12422149 (GG allele) Mutation Humans NA Prognostic Time to Progression p =0.028 Blood 23896625
1208 RNASEL [D541E variant: GG] Mutation Humans Expressed in patients with High Risk of PCa Prognostic High Risk with GG phenotype Vs High Risk with (TG and TT phenotype) p≤ 0.001 Blood 24046815
1209 RNASEL [R462Q variant: AA] Mutation Humans Expressed in patients with High Risk of PCa Prognostic High Risk with AA phenotype Vs High Risk with (AA and GA phenotype) p≤ 0.001 Blood 24046815
1210 Copy Number Variation: Deletion of 2p24.3 Mutation Humans Deletion found in Hispanic patients with High Risk PCa Prognostic High Risk Vs Low Risk p = 0.007 Blood 24054869
1249 Lactate Dehydrogenase [LDH] Protein Humans NA Prognostic Overall Survival Vs No Survival Univariate: p < 0.001; Multivariate: p =0.023 Blood 24255071
1250 Lactate Dehydrogenase [LDH] Protein Humans NA Prognostic Overall Survival Vs No Survival Univariate: p = 0.006 Blood 24255071
1308 C2orf43 [SNP: rs13385191] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.05 Blood 24411283
1309 PDLIM5 [SNP: rs17021918] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.01 Blood 24411283
1310 JAZF1 [SNP: rs10486567] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.001 Blood 24411283
1311 LMTK2 [SNP: rs6465657] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Blood 24411283
1312 MSMB [SNP: rs10993994] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Blood 24411283
1313 SNP: rs7127900 Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.01 Blood 24411283
1314 SNP: rs11672691 Mutation Humans Increased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.007 Blood 24411283
1315 KLK3 [SNP: rs2735839] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.002 Blood 24411283
1316 FRK [SNP: rs171866: AA versus gg/gA] Mutation Humans Increased risk of Progression Prognostic Progression Vs No Progression During ADT p=0.015 Blood 24448834
1317 DAB2 [SNP: rs268091: GC/CC versus GG] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.012 Blood 24448834
1318 DAB2 [SNP: rs268091: CC versus GG/GC] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.031 Blood 24448834
1319 EXOC4: [SNP: rs1149558: TT versus CC/CT] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.014 Blood 24448834
1320 EXOC4: [SNP: rs1149558: TT versus CC/CT] Mutation Humans Increased risk of Progression Prognostic All Cause Mortality Vs No Mortality during ADT p=0.005 Blood 24448834
1354 COMT [SNP: rs11705619: T>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.041 Blood 24682418
1355 COMT [SNP: rs165849: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.047 Blood 24682418
1356 COMT [SNP: rs9332377: C>T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.017 Blood 24682418
1357 CYP1B1 [SNP: rs1800440: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Blood 24682418
1358 NQO1 [SNP: rs2917670: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.039 Blood 24682418
1359 NQO2 [SNP: rs10223369: C>T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 24682418
1360 NQO2 [SNP: rs1143684: T>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.030 Blood 24682418
1361 NQO2 [SNP: rs6920900 G>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.007 Blood 24682418
1362 SULT2B1 [SNP: rs12460535: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.017 Blood 24682418
1363 SULT2B1 [SNP: rs2665582: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.037 Blood 24682418
1364 COMT [ SNP: rs16982844: C>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 24682418
1365 CYP1B1: [SNP: rs1800440: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0009 Blood 24682418
1366 SULT2B1: [SNP: rs10426628: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.025 Blood 24682418
1367 SULT2B1: [SNP: rs12460535: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.028 Blood 24682418
1368 SULT2B1: [SNP: rs2665582: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.07 Blood 24682418
1370 hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b; miRNA Humans NA Prognostic High Vs Intermediate Vs Low risk p<0.05 Blood 24661838
1384 mir-200c miRNA Humans Upregulated in Non Responders (Median NR/median R): 1.6 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.02 Blood 24714754
1385 mir-200b miRNA Humans Upregulated in Non Responders (Median NR/median R): 2.7 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.02 Blood 24714754
1386 mir-146a miRNA Humans Downregulated in Non Responders (Median NR/median R): 1.4 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.05 Blood 24714754
1387 mir-222 miRNA Humans Upregulated after Docetaxel treatment in Responders (1.4 fold) and Downregulated after Docetaxel treatment in Non Responders (1.1 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.01 Blood 24714754
1388 mir-301b miRNA Humans Upregulated after Docetaxel treatment in Responders (1.1 fold) and in Non Responders (1.6 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.04 Blood 24714754
1389 mir-20a miRNA Humans Upregulated after Docetaxel treatment in Responders (1.6 fold) and in Non Responders (1.1 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.04 Blood 24714754
1390 mir-200c + mir-200b + mir-146a miRNA Humans NA Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.001 Blood 24714754
1391 mir-222 + mir-301b + mir-20a miRNA Humans NA Predictive PSA responder Vs Non Responder -Post Docetaxel Change p = 0.02 Blood 24714754
1392 mir-200c + mir-200b + mir-146a+ mir-222 + mir-301b + mir-20a miRNA Humans NA Predictive PSA responder Vs Non Responder (Pre Docetaxel levels and Post Docetaxel Changes) p=0.001 Blood 24714754
1407 MIR605 [SNP: rs2043556: GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.006 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.005 Cohort 1+2: p=0.01 Blood 24740842
1408 MIR605 [SNP: rs2043556: AG/GG vs. AA] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.02 Blood 24740842
1409 MIR605 [SNP: rs2043556: GG vs. AA/AG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01 Blood 24740842
1410 MTRR [SNP: rs9332: CT] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.008 Cohort 1+2: p=0.01 Blood 24740842
1411 MTRR [SNP: rs9332: CT/TT vs. CC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.05 Blood 24740842
1412 CDON [SNP: rs3737336: CC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003 Blood 24740842
1413 CDON [SNP: rs3737336: CC vs. TT/TC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1+2: p=0.02;Multivariate: Cohort 1: p = 0.03; Cohort 1+2: p=0.007 Blood 24740842
1425 miR-7; miR-221; miRNA Humans Upregulated in Early Castration Resistant Acquisition Prognostic Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months) miR-7: p=0.034; miR-221: p=0.036; Blood 24760272
1453 Glutathione (GSH) Protein Humans Downregulated after treatment with SeMet for 9 months (0.22 ± 0.07 change from baseline) Predictive Baseline Vs 9 months later after treatment with SeMet p<0.05 Blood 24938534
1574 RNASEL (SNP: rs635261) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p= 0.002 Blood 25273821
1575 XRCC1 (SNP: rs915927) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p=0.009 Blood 25273821
1576 AKT1 (SNP: rs2494750) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p=0.016 Blood 25273821
1577 (Intergenic) KLK3–KLK2: [SNP: rs2735839] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.002 Blood 25274378
1578 JAZF1 [SNP: rs10486567] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.012 Blood 25274378
1579 (Intergenic) LILRB2–LILRA3 [SNP: rs103294] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.024 Blood 25274378
1580 (Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG/GG) Mutation Humans NA Prognostic Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) p=0.0002 Blood 25274378
1581 (Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG+AA/GG) Mutation Humans NA Prognostic Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) p=0.0005 Blood 25274378
1594 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA] Protein Humans Upregulated in GS ≤ 7 Prognostic Gleason Score <7 and Gleason Score ≤7 p<0.0001 Blood 25454615
1599 Methylation Status of IL-6 Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.03 Blood 26265203
1600 Methylation Status of ICAM-1 Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.02 Blood 26265203
1601 Methylation Status of IFN Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.02 Blood 26265203
1612 IL2RB [SNP: rs84460; C vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Blood 31035590
1613 SMAD3 [SNP: rs7162912; G vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0001 Blood 31035590
1614 FOXO3 [SNP: rs7762395 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 31035590
1615 FOXO3 [SNP: rs2153960 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 31035590
1616 SMAD3 [SNP: rs9302242; A vs G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.005 Blood 31035590
1617 IL4R [SNP: rs1805011; A vs C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.003 Blood 31035590
1618 IL4R [SNP: rs3024586; A vs G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.003 Blood 31035590
1619 CCL5 [SNP: rs2280789 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 31035590
1620 MMP9 [SNP: rs3918262; A Vs G] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.001 Blood 31035590
1621 VEGFR2 [SNP: rs7692791; C Vs T] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.001 Blood 31035590
1622 VEGFR2 [SNP: rs2034967; C Vs T] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.00000008 Blood 31035590
1646 NLR (neutrophil to lymphocyte ratio) Others Humans Upregulated in TRAMP Prognostic Overall Survival Vs No Survival p=0.0 Blood 30962764
1647 PLR (Platelet to lymphocyte ratio) Others Humans Upregulated in PCa Prognostic Overall Survival Vs No Survival p=0.0 Blood 30962764
1648 LMR (lymphocyte to monocyte ratio) Others Humans Downregulated in PCa Prognostic Overall Survival Vs No Survival p=0.0 Blood 30962764
1649 Neutrophil Others Humans NA Prognostic Overall Survival Vs No Survival p=0.006 Blood 30962764
1650 Monocyte Others Humans NA Prognostic Overall Survival Vs No Survival p=0.006 Blood 30962764
1651 NLR (neutrophil to lymphocyte ratio) Others Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0 Blood 30962764
1652 NLR (neutrophil to lymphocyte ratio) Others Humans NA Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.002 Blood 30962764
1653 LMR (lymphocyte to monocyte ratio) Others Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0 Blood 30962764
1654 Monocyte Others Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.006 Blood 30962764
1714 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 GG/AA] Mutation Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.003 Blood 26238235
1715 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA] Mutation Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.005 Blood 26238235
1716 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AA vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.032 Blood 26238235
1717 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 26238235
1718 TNKS2 (Tankyrase 2) [SNP: rs1539042 CG Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.032 Blood 26238235
1719 TNKS2 (Tankyrase 2) [SNP: rs1539042 CG/CC Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Blood 26238235
1749 Neutrophil to Lymphocyte Ratio (NLR) Others Humans NA Prognostic Cancer Specific Survival Vs No Survival p=0.011 Blood 30800682
1750 Neutrophil to Lymphocyte Ratio (NLR) Others Humans Upregulated in PCa: Fold change mean(BPH: 1.470; PCa: 54.384) Prognostic Overall Survival Vs No Overall Survival p=0.017 Blood 30800682
1770 PCA3 mRNA Humans Upregulated in Stage T3-T4 Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1771 hK2 mRNA Humans Downregulated in Stage T3-T4 Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1772 miR-141 miRNA Humans Upregulated in Bone Metastasis Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1773 tPSA+ hK2+ PCA3+ miR-141 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1774 Small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00070 Blood 30352818
1775 VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00056 Blood 30352818
1776 Cholesterol esters in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00058 Blood 30352818
1777 Cholesterol esters to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00062 Blood 30352818
1778 Cholesterol esters in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00002 Blood 30352818
1779 Cholesterol esters to total lipids ratio in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00111 Blood 30352818
1780 Cholesterol esters in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00107 Blood 30352818
1781 Cholesterol esters to total lipids ratio in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00139 Blood 30352818
1782 Free cholesterol in IDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00057 Blood 30352818
1783 Free cholesterol in large LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00080 Blood 30352818
1784 Free cholesterol in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00060 Blood 30352818
1785 Free cholesterol to total lipids ratio in medium HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00055 Blood 30352818
1786 Total cholesterol in HDL3 Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00109 Blood 30352818
1787 Total cholesterol in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00095 Blood 30352818
1788 Total cholesterol to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00105 Blood 30352818
1789 Total cholesterol in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.00001 Blood 30352818
1790 Total cholesterol to total lipids ratio in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00106 Blood 30352818
1791 Total cholesterol in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00132 Blood 30352818
1792 Total cholesterol to total lipids ratio in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00107 Blood 30352818
1793 Total cholesterol to total lipids ratio in small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00105 Blood 30352818
1794 Phospholipids in IDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00092 Blood 30352818
1795 Phospholipids to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00046 Blood 30352818
1796 Phospholipids to total lipids ratio in medium VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.00001 Blood 30352818
1797 Phospholipids in very small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00103 Blood 30352818
1798 Phospholipids to total lipids ratio in very small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00013 Blood 30352818
1799 Total lipids in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00035 Blood 30352818
1800 Triglycerides to total lipids ratio in medium VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00064 Blood 30352818
1801 Triglycerides to total lipids ratio small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00055 Blood 30352818
1802 Ratio of omega-6 Fatty Acids to total Fatty Acids Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00080 Blood 30352818
1803 Ratio of saturated Fatty acids to total Fatty acids Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00006 Blood 30352818
1804 Isoleucine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00008 Blood 30352818
1805 Leucine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00027 Blood 30352818
1806 Tyrosine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00003 Blood 30352818
1807 Valine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00139 Blood 30352818
1808 Albumin Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00065 Blood 30352818
1889 Interleukin 8 [SNP: rs4073 A vs T] Mutation Humans Isoform 2 of Eukaryotic translation initiation factor 2‐alpha kinase 4 (4 fold); Keratin type I cytoskeletal 10; SCO‐spondin (10 fold); Serum amyloid P‐component (4 fold); Apolipoprotein(a) (4 fold); Keratin, type I cytoskeletal 9 (3 fold); Ig kappa chain V‐IV region (2.4 fold); Isoform 2 of Filamin A (2.4 fold); Keratin, type II cytoskeletal 1(2.6 fold); Keratin, type II cytoskeletal 2 epidermal (2.3 fold); Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.002 Blood 30641210
1890 Interleukin 8 [SNP: rs4073 AA vs TT] Mutation Humans Ig heavy chain V‐III region BRO (0.1‐fold); Alpha‐1‐antitrypsin (0.1‐fold); Plasminogen (0.1‐ fold); Ig heavy chain V‐III region TIL (0.1‐fold); Hemopexin (0.1‐fold); Afamin (0.1‐fold); Inter‐alpha‐trypsin inhibitor heavy chain H1 (0.1‐fold); Protein AMBP (0.1‐fold); Alpha‐1B‐glycoprotein (0.03‐fold); Complement component C8 alpha chain (0.06‐fold); Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.002 Blood 30641210
1891 Interleukin 8 [SNP: rs4073 AA vs. TA+TT] Mutation Humans Downregulated in PCa: [4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; ] Upregulated in PCa: [1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone] Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.03 Blood 30641210
1892 Interleukin 8 [SNP: rs1126647 TT vs AA] Mutation Humans NA Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.02 Blood 30641210
1893 Interleukin 8 [SNP: rs1126647 TT vs AA + AT] Mutation Humans NA Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.02 Blood 30641210